Literature DB >> 35525861

Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis.

Luca Navarini1,2, Damiano Currado3, Annalisa Marino1, Stefano Di Donato1, Alice Biaggi1, Francesco Caso4, Luisa Costa4, Marco Tasso4, Piero Ruscitti5, Viktoriya Pavlych5, Onorina Berardicurti1, Antonio Ciancio6, Ilenia Pantano6, Federica Camarda7, Maria Sole Chimenti8, Arianna D'Antonio8, Francesco Ursini9, Addolorata Corrado10, Francesco Paolo Cantatore10, Roberto Perricone8, Giuliana Guggino7, Francesco Ciccia6, Paola Cipriani5, Raffaele Scarpa4, Antonella Afeltra1,2, Roberto Giacomelli1,2.   

Abstract

An accurate prediction of cardiovascular (CV) risk in patients with Axial Spondyloarthritis (axSpA) is a strong unmet need, as CV risk algorithms poorly perform in these subjects. The aim of this study was to establish whether the persistence of high C-reactive protein (CRP) and high disease activity may be considered predictive factors of CVD in axSpA. 295 patients without personal history of CVD, were consecutively enrolled in this study. To evaluate the relationship between CV events occurrence (fatal and non-fatal) and the persistence of increased CRP levels, ASDAS (Ankylosing Spondylitis Disease Activity Score) > 2.1, and BASDAI (Bath Ankylosing Spondylitis Disease Activity) > 4 during the follow-up, univariable and multivariable Cox Proportional Hazard Models have been performed. During follow-up (we analyzed 10-years retrospective data), 23 patients had a CV event. Multivariable Cox Proportional Hazard Models showed a strong association between CV event and the persistency of increased CRP levels (namely, percentage of visits in which CRP levels were increased) (HR = 1.03; 95%CI 1.015-1.045; p < 0.001), of ASDAS > 2.1 (HR = 1.014, 95%CI 1.000-1.028, p = 0.047), and of BASDAI > 4 (HR 1.019, 95%CI 1.006-1.033, p = 0.006) during follow-up, after adjustment for age, sex, and diabetes. This study suggests that persistence of increased CRP levels and high disease activity may be considered biomarkers to identify those axSpA patients at higher risk of CVD. Innovative axSpA-specific CV risk score, including these variables, have to be developed.
© 2022. The Author(s).

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35525861      PMCID: PMC9079083          DOI: 10.1038/s41598-022-11640-8

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.996


  31 in total

Review 1.  Cardiovascular Risk Assessment.

Authors:  Mark J Pletcher; Andrew E Moran
Journal:  Med Clin North Am       Date:  2017-07       Impact factor: 5.456

2.  Effect of including nonfatal events in cardiovascular risk estimation, illustrated with data from The Netherlands.

Authors:  Ineke van Dis; Johanna M Geleijnse; Jolanda Ma Boer; Daan Kromhout; Hendriek Boshuizen; Diederick E Grobbee; Yvonne T van der Schouw; Wm Monique Verschuren
Journal:  Eur J Prev Cardiol       Date:  2012-03-22       Impact factor: 7.804

3.  Moderate-to-severe plaque psoriasis, described by PASI ≥10%, can be associated with higher cardiovascular risk according to seven risk algorithms: Results of a 10-year single-center retrospective study and clinical management of psoriatic patients with cardiovascular risk.

Authors:  Claudio Conforti; Damiano Currado; Luca Navarini; Chiara Retrosi; Roberta Giuffrida; Enrico Zelin; Antonella Afeltra; Nicola di Meo; Caterina Dianzani; Iris Zalaudek
Journal:  Dermatol Ther       Date:  2020-11-14       Impact factor: 2.851

Review 4.  Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications.

Authors:  Bryant R England; Geoffrey M Thiele; Daniel R Anderson; Ted R Mikuls
Journal:  BMJ       Date:  2018-04-23

Review 5.  EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.

Authors:  R Agca; S C Heslinga; S Rollefstad; M Heslinga; I B McInnes; M J L Peters; T K Kvien; M Dougados; H Radner; F Atzeni; J Primdahl; A Södergren; S Wallberg Jonsson; J van Rompay; C Zabalan; T R Pedersen; L Jacobsson; K de Vlam; M A Gonzalez-Gay; A G Semb; G D Kitas; Y M Smulders; Z Szekanecz; N Sattar; D P M Symmons; M T Nurmohamed
Journal:  Ann Rheum Dis       Date:  2016-10-03       Impact factor: 19.103

6.  General cardiovascular risk profile for use in primary care: the Framingham Heart Study.

Authors:  Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

Review 7.  Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S).

Authors:  Jane Zochling
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

8.  Increased Cardiovascular Events and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients: 1 Year Prospective Single Centre Study.

Authors:  Piero Ruscitti; Paola Cipriani; Francesco Masedu; Silvio Romano; Onorina Berardicurti; Vasiliki Liakouli; Francesco Carubbi; Paola Di Benedetto; Saverio Alvaro; Maria Penco; Marco Valenti; Roberto Giacomelli
Journal:  PLoS One       Date:  2017-01-19       Impact factor: 3.240

9.  Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study.

Authors:  Julia Hippisley-Cox; Carol Coupland; Peter Brindle
Journal:  BMJ       Date:  2017-05-23
View more
  1 in total

Review 1.  Practical Significance of Biomarkers in Axial Spondyloarthritis: Updates on Diagnosis, Disease Activity, and Prognosis.

Authors:  Alexandra-Diana Diaconu; Alexandr Ceasovschih; Victorița Șorodoc; Cristina Pomîrleanu; Cătălina Lionte; Laurențiu Șorodoc; Codrina Ancuța
Journal:  Int J Mol Sci       Date:  2022-09-30       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.